

## EU validates PharmaZell Group's Cannabidiol (CBD) Ingredient for Novel Food

20. April 2021, Gropello.

The PharmaZell Group, a leading manufacturer of active pharmaceutical ingredients, is pleased to announce that its Italian production site Farmabios SpA has received a validation clearance from the European Commission ("EC"), and European Food Safety Authority ("EFSA") for its dossier on synthetic CBD as a Novel Food. This validation clearance is the first step in receiving a Novel Food authorization, which is now required for CBD products placed on the market in the European Union in accordance with Regulation (EU) 2015/2283.

The PharmaZell Group site Farmabios has also submitted a similar dossier at the UK Food Safety Agency (FSA), following Brexit, and expects to receive a UK approval in the next coming weeks.

Commenting on the validation, Farmabios' Managing Director Mario Di Giacomo said: "As always, the PharmaZell Group takes a science-led approach to deliver the highest-quality product possible and we are delighted that this has led to being one of the first companies in Europe to receive this validation clearance for CBD. It will allow us to service the Food and "Wellness" segments with our CBD ingredient, extending our reach beyond the Pharmaceutical industry, where our CBD is already used as an approved Active Pharmaceutical Ingredient."

PharmaZell Group produces CBD at the Farmabios site in Gropello, Italy, and has a fully validated process already scaled up to a commercial scale (up to tons quantities).

### About PharmaZell Group

The PharmaZell Group is made up of three core brands – PharmaZell, Farmabios and PharmaChol who supply the pharmaceutical industry with Active Pharmaceutical Ingredients and natural source materials. The Group operates production facilities in Germany, Italy and India and enables its companies to secure the industry's supply chain as trusted drug substance suppliers. Over 900 people work for the PharmaZell Group worldwide.

#### Key Group Facts:

- More than €200 million revenue in 2020
- Strong annual growth rate over the last decade
- A strong and competitive leader in its markets, ranked among the top three producers for most PharmaZell group products
- State-of-the-art proprietary, large-scale electrochemical processes
- Proprietary enzymatic route of synthesis for cholic acid derivatives

For more information please visit [www.pharmazell-group.com](http://www.pharmazell-group.com). For detailed information about the production site Farmabios please visit [www.farmabios.com](http://www.farmabios.com).